Navigation Links
Contract Research Organization, WCCT Global Announces Strong Focus for Early Phase Research for Obesity

Costa Mesa, Ca (PRWEB) March 25, 2013

Contract Research Organization, WCCT Global, today announced they are implementing a strong focus on clinical research for obesity treatments. The World Health Organization has alerted the public and medical community that obesity has been on the rise for the last 20 years and continues to grow. With this epidemic continually mounting, WCCT Global is focusing resources on early phase research to treat individuals suffering from obesity. They have done this by establishing a database of over 7,000 people who are stratified by BMI and can be categorized as either overweight or obese. These individuals have expressed the desire to participate in clinical research in obesity. There are four areas of research that would coincide with the characteristics of the WCCT Database: weight loss (appetite suppressant), type 2 diabetes, hypertension and cholesterol / triglyceride control. The demand for safe and reliable treatments for these obesity-associated morbidities is growing at a rapid rate. WCCT Global has conducted multiple clinical studies in all three of these areas. Dr. Mel Affrime, Sr.VP, Translational Medicine for WCCT Global states, “Obesity is a leading cause of death in millions of people each year. The obesity epidemic only continues to grow as many of us continue to live unhealthy lifestyles with our unhealthy diet and lack of regular exercise. Therefore, WCCT Global looks forward to participating in the public health efforts in obesity to hopefully begin to control of this problem within the next decade.”

WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like to request information about how WCCT Global can assist your organization with a clinical study, please CLICK HERE.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Arizona State University secures defense contract
2. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
3. Local Woodinville Contractor, Washington State Kitchen and Bath, Combats Toxic Mold, Adhering to the Toughest Mold Protection Standards in the Nation with New Promotion
4. Collagenase for Dupuytrens contracture: Added benefit not proven
5. BMC awarded contract to study validity of primary care drug screening tools
6. Federal government renews contract for collecting and maintaining national stem cell transplantation database
7. NIH awards Georgia malaria research consortium up to $19.4 million contract
8. Care2Learn/Upstairs Solutions and Jarlette Health Services Sign Multi-Year Contract for Online Training and Record-Keeping
9. NHS consultant contract fails to increase productivity
10. PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
11. Securityhunter, Inc. Selected as a Top 25 Baltimore Defense Contractor for the Baltimore Business Journal's 2013 Book of Lists
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: